학술논문

The IRF5–TNPO3 association with systemic lupus erythematosus has two components that other autoimmune disorders variably share
Document Type
article
Author
Kottyan, Leah CZoller, Erin EBene, JessicaLu, XiaomingKelly, Jennifer ARupert, Andrew MLessard, Christopher JVaughn, Samuel EMarion, MirandaWeirauch, Matthew TNamjou, BahramAdler, AdamRasmussen, AstridGlenn, StuartMontgomery, Courtney GHirschfield, Gideon MXie, GangColtescu, CatalinaAmos, ChrisLi, HeIce, John ANath, Swapan KMariette, XavierBowman, SimonRischmueller, MaureenLester, SueBrun, Johan GGøransson, Lasse GHarboe, ErnaOmdal, RoaldCunninghame-Graham, Deborah SVyse, TimMiceli-Richard, CorinneBrennan, Michael TLessard, James AWahren-Herlenius, MarieKvarnström, MarikaIllei, Gabor GWitte, TorstenJonsson, RolandEriksson, PerNordmark, GunnelNg, Wan-FaiAnaya, Juan-ManuelRhodus, Nelson LSegal, Barbara MMerrill, Joan TJames, Judith AGuthridge, Joel MScofield, R HalAlarcon-Riquelme, MartaBae, Sang-CheolBoackle, Susan ACriswell, Lindsey AGilkeson, GaryKamen, Diane LJacob, Chaim OKimberly, RobertBrown, ElizabethEdberg, JeffreyAlarcón, Graciela SReveille, John DVilá, Luis MPetri, MichelleRamsey-Goldman, RosalindFreedman, Barry INiewold, TimothyStevens, Anne MTsao, Betty PYing, JunMayes, Maureen DGorlova, Olga YWakeland, WardRadstake, TimothyMartin, EzequielMartin, JavierSiminovitch, KatherineSivils, Kathy L MoserGaffney, Patrick MLangefeld, Carl DHarley, John BKaufman, Kenneth M
Source
Human Molecular Genetics. 24(2)
Subject
Biological Sciences
Genetics
Autoimmune Disease
Biotechnology
Lupus
Aetiology
2.1 Biological and endogenous factors
Inflammatory and immune system
Autoimmune Diseases
Bayes Theorem
Case-Control Studies
Cohort Studies
DNA-Binding Proteins
Haplotypes
Humans
Interferon Regulatory Factors
Lupus Erythematosus
Systemic
Male
Polymorphism
Single Nucleotide
Promoter Regions
Genetic
beta Karyopherins
UK Primary Sjögren's Syndrome Registry
Medical and Health Sciences
Genetics & Heredity
Language
Abstract
Exploiting genotyping, DNA sequencing, imputation and trans-ancestral mapping, we used Bayesian and frequentist approaches to model the IRF5-TNPO3 locus association, now implicated in two immunotherapies and seven autoimmune diseases. Specifically, in systemic lupus erythematosus (SLE), we resolved separate associations in the IRF5 promoter (all ancestries) and with an extended European haplotype. We captured 3230 IRF5-TNPO3 high-quality, common variants across 5 ethnicities in 8395 SLE cases and 7367 controls. The genetic effect from the IRF5 promoter can be explained by any one of four variants in 5.7 kb (P-valuemeta = 6 × 10(-49); OR = 1.38-1.97). The second genetic effect spanned an 85.5-kb, 24-variant haplotype that included the genes IRF5 and TNPO3 (P-valuesEU = 10(-27)-10(-32), OR = 1.7-1.81). Many variants at the IRF5 locus with previously assigned biological function are not members of either final credible set of potential causal variants identified herein. In addition to the known biologically functional variants, we demonstrated that the risk allele of rs4728142, a variant in the promoter among the lowest frequentist probability and highest Bayesian posterior probability, was correlated with IRF5 expression and differentially binds the transcription factor ZBTB3. Our analytical strategy provides a novel framework for future studies aimed at dissecting etiological genetic effects. Finally, both SLE elements of the statistical model appear to operate in Sjögren's syndrome and systemic sclerosis whereas only the IRF5-TNPO3 gene-spanning haplotype is associated with primary biliary cirrhosis, demonstrating the nuance of similarity and difference in autoimmune disease risk mechanisms at IRF5-TNPO3.